Hyper Terminal logo
Company earnings

GRCE Earnings Date & History

Grace Therapeutics, Inc (NASDAQ NMS - GLOBAL MARKET) earnings schedule, consensus estimates and reported results for the last eight quarters.

Last updated Oct 29, 2026 at 12:39 AM ET

Grace Therapeutics, Inc

Pharmaceuticals

Next earnings date
Monday, November 16, 2026
Reporting session
Time TBD
EPS estimate
$-0.15
Revenue estimate
$0

Research beyond the earnings headline

What’s happening around GRCE?

Congressional Trading

Review purchases and sales when available, transaction and disclosure dates kept separate

Members-only details

Previews show an example layout only, not data for GRCE. Coverage varies by company.

GRCE earnings history

Report dateQuarterEPS est.EPS actualSurpriseRevenue
Thursday, August 13, 2026Q1 2027$-0.13$-0.13+2.0%$0
Thursday, June 18, 2026Q4 2026$-0.23$-0.06+74.4%$0
Thursday, February 12, 2026Q3 2026$-0.29$-0.14+51.0%$0
Thursday, November 13, 2025Q2 2026$-0.19$-0.06+68.2%$0

What the market is watching in GRCE's next report

  • The full Earnings Read for this company: focus areas, peer read-through and prior-reaction context.
  • Ticker Read combines trend, relative strength and catalysts in one research view.
  • Scanners, daily catalyst context and the members-only Weekly Watchlist are included.
Free by email

Get the week's earnings by email

One free email each week: the reports that matter, when they land, and what the market is watching.

No account required. Unsubscribe any time. Research and education only, not investment advice.

Frequently asked questions

Calendar data is provided for educational and research purposes only and is not investment advice. Release dates, times, estimates and results can change; always verify against the issuing company or agency.

GRCE earnings discussion

Anyone can read. Any free Hyper Stocks account can join in.

Create a free account to join the discussion. Reading is open to everyone, commenting is free, no subscription needed.

Loading discussion…

Member comments are opinions from individual users, not Hyper Stocks research, and are never personalised investment advice.